Condition: Indolent B-Cell Non-Hodgkin Lymphoma · Recurrent Indolent B-Cell Non-Hodgkin Lymphoma · Refractory Indolent B-Cell Non-Hodgkin Lymphoma · Sponsor: Mayo Clinic
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.
This description comes directly from the study's public registry record.
Clinical Trials Referral Office · 855-776-0015 · mayocliniccancerstudies@mayo.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic in Arizona | Scottsdale, Arizona, United States | Recruiting |
| Mayo Clinic in Florida | Jacksonville, Florida, United States | Recruiting |
| Mayo Clinic Health System in Albert Lea | Albert Lea, Minnesota, United States | Recruiting |
| Mayo Clinic Health System - Mankato | Mankato, Minnesota, United States | Recruiting |
| Mayo Clinic in Rochester | Rochester, Minnesota, United States | Recruiting |
| Mayo Clinic Health System-Eau Claire Clinic | Eau Claire, Wisconsin, United States | Recruiting |
| Mayo Clinic Health System-Franciscan Healthcare | La Crosse, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06386315